Adverse Experience Reporting. (a) Prior to enrollment of Subjects in the Study, the Parties shall enter into a pharmacovigilance agreement setting forth the Parties’ responsibilities and obligations with respect to the procedures and timeframes for compliance with Applicable Law pertaining to safety reporting of the respective Molecules and the Combination (“PV Agreement”).
Appears in 4 contracts
Samples: Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.), Combination Study Agreement (Corvus Pharmaceuticals, Inc.), Ib Combination Study Agreement (Corvus Pharmaceuticals, Inc.)